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Abstract 
Background 
A minority of injecting drug users, termed exposed uninfected (EU), are resistant to hepatitis 
C (HCV) infection despite repeated low-dose exposures. We identify for the first time a 
cohort of blood recipients who remained uninfected despite large-dose exposure to HCV-
contaminated blood and characterise immune factors that may confer protection. 
 
Methods 
Of 1340 blood recipients from the Look Back database who were transfused HCV-
contaminated blood, we identified 8 who remained uninfected. In these 8 EUs, we 
characterised their natural killer (NK) cell populations and HCV-specific T cell responses.  
Findings were compared with 10 spontaneous resolvers of HCV infection, 10 patients with 
chronic HCV infection, and 10 healthy controls.  
 
Results 
EUs had significantly greater numbers of NK cells with the activating receptor NKp30+ on 
CD56bright and CD56dim subsets compared with other groups (p<0.05). Following interleukin-
2 activation, NK cells of EUs had enhanced  cytotoxicity that  positively correlated with 
NKp30 expression (p=0.02). Differences in NKp80 and KIR2DL3 expression were also 
observed. HCV-specific T cell responses were observed in some EUs but of low amplitude. 
 
Conclusion 
Exposure without infection following transfusion of HCV-contaminated blood is a very rare 
phenomenon and suggests a high level of resistance to infection. Enhanced NK cell activation 
and killing, with weak HCV-speecific T cell responses, were  observed many years after 
exposure in uninfected recipients and may contribute to protection from  HCV acquisition, 
although additional protective factors are being sought in this important cohort. 
 
Keywords 
Hepatitis C; exposed uninfected; natural killer cells; innate immunity; natural cytotoxicity 
receptor; NKp30  
Hepatitis C virus (HCV) is an important cause of liver disease with a propensity to establish 
chronic infection. Only a minority of individuals are able to spontaneously clear the virus, 
which relies on the host mounting a successful immune response [1-3]. Not all individuals 
exposed to HCV, however, develop infection. We and others have previously reported on a 
novel phenotype of injecting drug users (IDUs) who have no evidence of infection, such as 
viraemia or anti-HCV antibodies (Ab), despite repeated HCV exposure through high-risk 
practices [4-16]. We have termed these individuals exposed uninfected (EU) [17]. 
 
Thus far, studies on EUs have focused on IDUs exposed to low doses of the virus. The 
phenomenon of exposure without infection has not been previously described in individuals 
parenterally exposed to large doses of HCV, such as following transfusion of contaminated 
blood products. In this study, we have identified and characterised a novel cohort of 
recipients of HCV-contaminated blood products who have no clinical or serological evidence 
of infection and who appear to be immunologically distinct from spontaneous resolvers 
(SRs). Innate and adaptive immune factors that might contribute to this protection against 
HCV were examined, with a focus on natural killer (NK) cells. 
 
NK cells are defined as CD3- CD56+ and play a key part in the early innate response to viral 
infections. Unlike T and B cells, they do not require priming and so are able to rapidly kill 
virus-infected cells [18]. Their activation status is governed by surface receptors with 
activating and inhibitory functions [19]. EU IDUs appear to be immunologically distinct from 
those with resolved or chronic infection, displaying an enhanced innate immune response 
[17,20] attributed to increased NK cell activity. Two studies followed a population of IDUs at 
high risk for HCV exposure and observed that in IDUs who remained uninfected, their NK 
cells demonstrated increased cytotoxic activity and interferon-gamma (IFN-γ) production 
when compared with IDUs who became infected [7,8]. EU IDUs also possessed NK cells 
with a specific receptor profile, which might represent a subset with a favourable phenotype 
that are more readily activated to kill, thereby preventing establishment of infection [7-9]. 
These findings have thus far been demonstrated in EUs exposed to only low doses of HCV. 
This study reports on the immune characteristics of a novel cohort of EUs exposed to a much 
larger inoculum of virus via blood transfusion.  
Materials and methods 
Study population 
The study population consisted of blood recipients identified from the NHS Look Back 
programme as being exposed to HCV via blood transfusion pre-1991, which was prior to 
universal HCV donor screening in the UK.  
 
The Look Back programme was established in 1995 to trace and test recipients of blood 
products previously donated by blood donors who were subsequently found to be HCV 
positive when screening was introduced. We have reviewed the Look Back cohort to identify 
those who did not develop any evidence of HCV infection despite confirmed high-dose 
exposure to HCV-contaminated blood products. We compared findings in these exposed 
uninfected cases with others who developed chronic infection or spontaneously resolved 
infection.  
 
EU cohort 
From a total of 1340 blood recipients identified in the Look Back programme, eight EU cases 
were stringently selected. The following criteria were used: 
1) Definitive history of exposure to HCV from blood products; 
2) Both HCV Ab and HCV ribonucleic acid (RNA) undetectable;  
3) All EU cases received blood from HCV-infected donors whose blood donations had 
transmitted HCV to at least one recipient before and one recipient after donating blood to that 
EU individual, providing confirmation that the donor was infectious at the time of donation;  
or, the EU individual had to have received part of a blood donation that was responsible for 
infecting another recipient, thus confirming the donation itself was contaminated.  
 
SR cohort  
The SR cohort consisted of 10 blood recipients recruited from the Look Back programme 
who spontaneously cleared HCV following infection via blood transfusion, defined as anti-
HCV Ab positive and HCV RNA negative.  
 
Chronic infection cohort  
A cohort of 10 treatment naïve patients with blood transfusion-acquired genotype 1 chronic 
HCV infection (anti-HCV Ab and HCV RNA positive for at least six months) were recruited 
from the South West Liver Unit clinic at Derriford Hospital, Plymouth.  
 
Healthy control cohort 
A cohort of 10 healthy controls with no risk factors for HCV was also recruited from 
Derriford Hospital and University of Plymouth.  
 
Timing of HCV testing 
All EU and SR blood recipients recruited from the Look Back programme were tested for 
HCV at the time of the programme (1995-1997) for anti-HCV Ab by a third-generation 
enzyme immunoassay (EIA) and HCV RNA by polymerase chain reaction (PCR). Median 
time from transfusion to the initial anti-HCV Ab testing was 7.4 years (interquartile range 
[IQR] 6.1-9.3) in EUs and 7.1 years (IQR 4.9-10.7) in SRs.  
 
At study entry, each blood recipient was re-tested for anti-HCV Ab using a fourth-generation 
EIA assay, Monolisa HCV Ag-Ab Ultra (Bio-Rad Laboratories, Hertfordshire, UK), and for 
HCV RNA by PCR using the Cobas Ampliprep/Cobas Taqman HCV Test v2.0 (Roche, 
California, United States; lower limit of detection 15 IU mL-1).  
Ethics 
Ethics approval was granted by the UK Research Ethics Committee. All procedures were 
performed in accordance with the ethical standards of the Helsinki Declaration (1964, 
amended 2008) created by the World Medical Association. All participants provided 
informed written consent. 
 
Peripheral blood mononuclear cells (PBMCs) isolation 
PBMCs were isolated from whole blood using Ficoll (Sigma-Aldrich, Dorset, UK) density 
gradient centrifugation and cryopreserved for subsequent analyses [4,5].  
 
Flow cytometry 
Flow cytometry was performed using a four-channel BD Accuri C6 instrument (New Jersey, 
USA). Thawed PBMCs (1x106) were stained with the appropriate fluorescent-labelled 
monoclonal Ab/isotype, washed, and analysed. Ab labelled with FITC/PE/PerCP-Cy5.5/APC 
specific for the following human cell surface antigens were used: CD3, CD56, and CD16 
from BD Biosciences (Oxford, UK); and KIR2DL1, CD158b, KIR2DL3, KIR2DL4, 
KIR2DS4, KIR3DL1, KIR3DL2, NKp30, NKp44, NKp46, NKG2A, NKG2C, and NKG2D 
from R&D Systems (Oxford, UK).  
 
Cytotoxicity assay 
Natural and interleukin (IL) 2-induced cytotoxicity of NK cells were measured against the 
target cell K562. NK cells were isolated from PBMCs using negative selection with the NK 
Cell Isolation Kit (Miltenyi Biotec, Surrey, UK). Isolated NK cells were cultured 
with/without IL2 (25 ng mL-1; R&D Systems) for 48 hours. Following culture, K562 cells, 
labelled with carboxyfluorescein succinimidyl ester (Fisher-Scientific, Leicester, UK), were 
added to NK cells at an effector-to-target cell ratio of 0:1 (negative control) or 10:1 and 
incubated for four hours. Finally, 7-aminoactinomycin D (BD Biosciences) was added prior 
to flow cytometry.  
 
IFN-γ production 
Thawed PBMCs were stimulated with phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 
ionomycin (Sigma-Aldrich) in the presence of brefeldin A (BD Golgi Plug, BD Biosciences) 
prior to incubation for four hours. After stimulation, cells were stained for CD3 and CD56 
and then fixed and permeabilised using the BD Cytofix/Cytoperm Plus 
Fixation/Permeabilisation Kit (BD Biosciences). Following this, the cells were stained with 
fluorescent-labelled Ab for intracellular IFN-γ (BD Biosciences), washed, and analysed on 
the flow cytometer. Unstimulated PBMCs served as the negative control. 
 
IFN-γ enzyme-linked immunospot (ELISpot) assay 
ELISpot assays were performed as previously described [4,5]. Briefly, 200,000 PBMCs per 
well were cultured in triplicate with HCV peptides. The peptides spanned the entire genome 
of HCV genotypes 1b and 3a (BEI Resources, Virginia, United States) and were grouped into 
eight pools per genotype (core, E1, E2, p7 and NS2, NS3, NS4, NS5a, NS5b). Positive 
controls were: leucoagglutinin (PHA-L; Sigma-Aldrich); cytomegalovirus, Epstein-Barr 
virus, and influenza virus peptide pool (ProImmune, Oxford, UK); and cytomegalovirus pp65 
peptide pool (ProImmune). Cells cultured in media alone acted as the negative control. After 
16 hours of culture, the PBMCs were plated onto an ELISpot plate (Merck Millipore, 
Hertfordshire, UK) coated with IFN-γ Ab (BD Biosciences).  
 
The mean number of spots was calculated for each triplicate. The number of spots in the 
negative control wells was subtracted from that of the antigen-treated wells and results 
expressed as spot-forming units per million cells (SFU per 106 PBMCs). Assays with high 
background (negative control greater than five spots per well) or absent PHA-L responses 
were excluded. A response was defined as positive if the mean response in the antigen-treated 
well was more than twice the background value in the negative well and greater than three 
standard deviations above the mean response in the corresponding well of the healthy 
controls. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics v20. Results were expressed as 
medians unless stated otherwise. Categorical data were compared using Fisher’s exact test. 
Continuous data between two cohorts were compared using Mann-Whitney-U test. With 
more than two cohorts, continuous data were compared using Kruskal-Wallis test. A 
statistically significant Kruskal-Wallis test was followed by post-hoc analysis using Dunn’s 
test for multiple comparisons between cohorts. Adjusted p values were calculated to correct 
for multiple comparisons. Pearson product-moment correlation coefficient (r) was calculated 
for correlation analysis. A line of best fit was drawn using linear regression. Statistical 
significance levels were determined by two-tailed tests (p <0.05).   
Results 
Of the 1340 blood recipients identified as having received a contaminated blood product, 13 
(0.97%) met the inclusion criteria for EU.  Eleven were alive, of which eight were recruited 
into the study.  
 
Baseline demographics and transfusion details of the eight EUs are shown in Table 1. Median 
age at time of transfusion was 21 years (IQR 13-32). There was no history of post-transfusion 
hepatitis. One participant, EU5, had biopsy-proven non-alcoholic fatty liver disease; the 
remaining seven had no history of liver disease or abnormal liver enzymes. There was a range 
of active medical conditions. No participant was on steroids or immunosuppression at the 
time of transfusion or recruitment.  
 
Table 2 shows the donor-recipient records for each of the donors that donated blood to our 
EUs. In five cases, the donors (X1, X2, X3, X5, X7) infected other recipients both before and 
after donating blood to our EUs (EU1, EU2, EU3, EU5, EU7, respectively), confirming the 
donors were infectious during this time. In the remaining three cases, donors X4, X6, and X8 
each made a donation that was separated into components and transfused to more than one 
recipient (X4 to EU4 and R9; X6 to EU6 and R13; X8 to EU8 and R19). The other recipients 
developed infection, thereby confirming the donation itself, which the three EUs had also 
received, was contaminated. In all cases, the genotypes of the infected recipients matched 
those of their respective donors. 
 
A further 10 participants were recruited into each of the remaining three cohorts.  There were 
no significant differences in the baseline characteristics between the four cohorts.  Median 
ages at study entry were: 45 years (IQR 36-59) for the EU cohort, 67 years (IQR 47-71) for 
the SR cohort, 52 years (IQR 43-61) for the cohort with chronic infection, and 46 years (IQR 
39-53) for the healthy controls. In the EU, chronic infection, and healthy control cohorts, 
50% were male; in the SR cohort, 40% were male.  
 
EU blood recipients possessed higher numbers of NKp30+ NK cells 
Fourteen activating and inhibitory NK cell receptors were studied on flow cytometry. NK 
cells were visualised as CD3- CD56+. The two functional subsets of NK cells, CD56bright and 
CD56dim, were defined by the varying intensities of CD56 expression. EUs were observed to 
have a higher proportion of NK cells than healthy controls and those with chronic infection 
(Figure 1); however, there was no difference in the distribution of NK cell subsets between 
EUs and the other cohorts, suggesting that the higher relative frequencies of NK cells in EUs 
were due to an increase in both CD56bright and CD56dim cells.  
 
The numbers of NKp30+ NK cells were significantly higher in EUs than in the other cohorts 
– vs. SRs (p=0.002), vs. healthy controls (p=0.01), and vs. patients with chronic infection 
(p=0.04) (Figure 2A). This increased expression of NKp30 in EUs was observed across both 
subsets. EUs had significantly greater numbers of CD56dim NKp30+ cells when compared to 
SRs (p=0.007) and healthy controls (p=0.03), and trending towards significance when 
compared with the chronic infection cohort (p=0.06) (Figure 2B). In the CD56bright subset, 
numbers of NKp30+ cells were highest in the EUs, significant against SRs (p=0.047), healthy 
controls (p<0.001), and those with chronic infection (p=0.02) (Figure 2C). 
 
Other differences in receptor expression were also observed. There were significantly higher 
levels of NKp80+ NK cells in EUs and SRs than in healthy controls, although not so when 
compared with the chronic infection cohort (Figure 3A). The expression of the inhibitory NK 
cell receptors was also examined. The only significant difference was observed with the killer 
cell immunoglobulin-like receptor, KIR2DL3, which was preferentially expressed on 
CD56bright NK cells of both EUs and SRs (Figure 3B).  
 
NKp30-high NK cells demonstrated enhanced IL2-induced cytotoxicity 
Cytotoxic activity of isolated NK cells (>90% purity) was determined to confirm whether 
differences in receptor expression were associated with enhanced killing potential. NK cells 
at rest had little cytotoxic activity and no differences were detected between cohorts. 
Following IL2 activation, NK cells of EUs had greater cytotoxicity than the other cohorts – 
vs. SRs (p=0.06), vs. healthy controls (p=0.01), and vs. those with chronic infection (p=0.04) 
(Figure 4A). As NKp30 was the only receptor that was preferentially upregulated in EUs, we 
looked for a potential relationship between NKp30 expression and NK cell cytotoxicity. IL2-
induced NK cell cytotoxicity was positively correlated with NKp30 expression, although this 
correlation was weak (r=0.38; p=0.02) (Figure 4B).  
 
NK cells can kill virus-infected cells indirectly by rapidly producing IFN-γ. At rest, very few 
NK cells produced IFN-γ with no differences observed between cohorts. Following 
stimulation, NK cell production of IFN-γ was increased in all subjects, although to a lesser 
extent in those with chronic infection. IFN-γ production by CD56dim and CD56bright NK cells 
in EUs was no different from SRs and healthy controls.  
 
T cell-mediated IFN-γ responses to HCV 
T cell responses to genotypes 1b and 3a were assessed in the eight EUs and compared with 
eight healthy controls. Positive IFN-γ responses were observed only in the EU group, with 
4/8 demonstrating a positive response to at least one HCV-related peptide compared with 
none in the healthy control group. Although the positive responses in the four EUs were 
weak, they were all multi-specific i.e. directed against multiple HCV proteins, which support 
true exposure rather than cross-reactivity with a non-HCV epitope. HCV proteins that were 
targeted were genotype 1b core, NS3, NS4, and NS5B proteins, and genotype 3a core, NS3, 
and NS5A proteins. The median times from HCV exposure to ELISpot testing in EUs were 
not significantly different between those with positive responses (23.6 years) and those 
without (25.3 years).  
Discussion 
This study describes a novel cohort of blood recipients with no clinical or serological 
evidence of infection despite verified exposure to HCV-contaminated blood. This is the first 
report of exposure without infection in the setting of large-volume intravenous inoculation of 
HCV with 8 cases identified and traced after meticulous interrogation of the records from a 
well conducted national look back exercise dating back to the 1990’s. Prior to this, exposure 
to HCV that did not result in infection had only been reported following much smaller 
inocula through IDU [4-16], sexual contact [21-23], or needle stick injury [24].  Transfusion-
related HCV is, by and large, historical and so this cohort has considerable potential to 
advance our understanding of how high level resistance to HCV infection can be conferred.  
 
We have shown that EU blood recipients have distinct differences in their NK cell phenotype 
and function. EUs had greater proportions of NK cells in the periphery, with a relative 
increase in both CD56bright and CD56dim subsets. One of the main findings was an activated 
receptor phenotype in EUs, with greater numbers of NKp30+ cells in both the CD56bright and 
CD56dim subsets, significantly higher than in the other groups. Thus, EU blood recipients not 
only possessed higher frequencies of NK cells, but their NK cells were richer in NKp30 
compared to blood recipients with resolved or chronic infection. On functional analysis, 
activated NK cells in EUs displayed greater killing potential, with increased cytotoxicity but 
similar IFN-γ production. This enhanced killing potential of NK cells in EUs positively 
correlated with the expression of NKp30. These findings mirror those of two prospective 
studies conducted on IDUs; Sugden et al. [7] and Golden-Mason et al. [8] reported that 
increased NK cell cytotoxicity protected IDUs exposed to HCV from becoming infected and 
this enhanced cytotoxicity was associated with higher expression of NKp30. This study, 
therefore, supports NKp30-mediated NK cell cytotoxicity as a potential mechanism by which 
individuals exposed to HCV are protected from infection, and appears to be relevant in both 
low- and high-dose exposures.  
 
Other less striking differences were observed. NKp80 has an activating function, possibly by 
acting as co-receptor with other activating receptors [25]. EUs and SRs had significantly 
higher frequencies of NKp80+ NK cells than healthy controls, although levels were not 
statistically different when compared with those chronically infected. The significance of 
increased NKp80 levels is unclear; NKp80 has not previously been implicated in the immune 
defence against HCV. The levels of NKp80 did not correlate with cytotoxic activity, which 
could support the hypothesis that NKp80 alone has a limited role in NK cell activation, but 
acts instead as a co-receptor to potentiate the effect of a key receptor, such as NKp30.  
 
KIR2DL3 has been associated with a favourable outcome following infection. HCV-infected 
IDUs have a higher chance of spontaneous clearance if they are homozygous for KIR2DL3 
and HLA-C1.  KIR2DL3 is a weaker inhibitor of NK cell activation than other inhibitory 
KIRs; thus, NK cells carrying this receptor are more easily activated [26]. The beneficial 
effect of KIR2DL3 and HLA-C1 extends beyond resolving infection, with our group and 
others showing that it may also play a part in preventing infection in IDUs exposed to HCV 
[9,13,15]. We now find KIR2DL3 to be associated with a favourable outcome in the setting 
of transfusion-related HCV exposure. Increased expression of KIR2DL3 was detected in both 
EUs and SRs, but only in the CD56bright subset. KIRs are usually expressed at minimal levels 
on CD56bright NK cells. Hence, upregulation of KIR2DL3 might render CD56bright cells more 
easily activated and enhance their functional activity against HCV.  
 
In this study, half of EU blood recipients demonstrated IFN-γ-producing T cell responses to 
HCV, similar to rates reported in both our [5] and other [7,10-12,24] IDU EU cohorts, where 
up to 60% have demonstrable T cell responses. Whilst these responses are often to multiple 
viral antigens, they are typically much weaker than those seen in SRs and the degree to which 
T cell responses confer protection from HCV infection is controversial.  A nested case 
control series from a prospectively studied cohort of IDUs in Australia revealed no 
differences in T cell responses between those who developed incident HCV infection and 
those who remained uninfected, suggesting that whilst HCV-specific cellular immunity is 
prevalent in EUs, it does not correlate with protection [7]. Thus, whilst the presence of low-
level HCV-specific T cell responses in half of our EU blood recipients provides further 
confirmation of HCV exposure, any role they have in protection remains unclear. The 
absence of response in the remaining EU blood recipients is consistent with previous studies 
that showed T cell responses waning over time [4,6], with HCV exposure in these recipients 
dating back over 20 years.  
 
There are some limitations to this study. We defined EUs as being HCV antibody and HCV 
RNA negative. However, as the first testing for HCV antibodies took place some years after 
exposure, it is possible that they were infected but lost HCV antibodies over time. This has 
been reported in SRs, but typically 18-20 years after a low dose inoculation from anti-D 
immunoglobulin [27], whereas EUs identified in this cohort were all tested within 10 years 
from exposure. The sample size was limited by the small number of uninfected individuals 
that met the very strict definition of HCV exposure. EU blood recipients represent an 
extremely rare cohort and therefore, any study examining this unique group will be limited by 
small numbers and the difficulties that this poses. Furthermore, our results, like other studies 
on EU cohorts [4-16], were based on experiments using peripheral blood samples to obtain 
NK and T cells, when we know that the immune response to the virus is reliant on 
intrahepatic immune cells. However, to study intrahepatic immune cells would require 
invasive sampling of the liver, which is difficult to justify in EUs who are otherwise healthy.  
 
In summary, we have defined a novel cohort with a uniquely high level of resistance to HCV 
infection. This small group of cases, identified and traced from a painstaking review of a 
much larger cohort of HCV-exposed blood recipients, remained uninfected despite a clear 
history of high-dose parenteral exposure to HCV-contaminated blood. These EU blood 
recipients, similar to IDU EU cases, demonstrate distinct differences in their innate 
immunity, with an activated NK cell phenotype and enhanced cytotoxicity, together with low 
level adaptive HCV-specific T cell responses in half of these cases identified many years 
after the HCV exposure. It remains unclear if these differences alone are sufficient to explain 
the high level resistance demonstrated by these unusual cases and further study of this 
important group of cases to identify other potential mechanisms of protection from HCV 
infection are ongoing.     
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Table 1. Baseline demographics and clinical characteristics of the eight EU participants 
ID Age at 
study 
entry    
(yrs) 
Sex
M/F 
Ethnicity 
 
Date 
transfused 
Type of 
product  
Indication 
 
Other 
HCV 
risks 
Symptoms 
of hepatitis 
Abnormal 
liver 
enzymes 
Active medical 
conditions 
Immuno
suppress
ion 
EU1 52 M White British 05/08/1982 RBC Trauma No No No Hypertension No 
EU2 41 F White British 07/01/1985 Platelet Childhood ITP No No No No No 
EU3 32 M White British 07/04/1987 
Whole 
blood 
Facial surgery No No No Gout No 
EU4 72 F White British 01/02/1989 RBC Hysterectomy No No No 
Hypertension, type 
II diabetes 
No 
EU5 61 F White British 20/02/1989 
Whole 
blood 
Menorrhagia No No NAFLD 
Hypothyrodism on 
replacement 
No 
EU6 48 M 
Afro-
Caribbean 
British 
21/06/1990 RBC Renal failure No No No Haemodialysis No 
EU7 42 F 
Afro-
Caribbean 
British 
29/10/1990 RBC 
Sickle cell 
anaemia 
No No No Sickle cell anaemia No 
EU8 34 M White British 25/11/1990 RBC Bone surgery No No No Asthma No 
EU, exposed uninfected; yrs, years; M, male; F, female; HCV, hepatitis C; RBCs, red blood cells; ITP, idiopathic thrombocytopaenic purpura; NAFLD, non-
alcoholic fatty liver disease 
Table 2. Donations made by the donors of the eight EU participants and their 
corresponding recipients 
Donor Donation Recipient Transfusion date HCV test result by Lookback Programme 
X1 1 R1 17/03/1981 Infected – chronic HCV 
 2 EU1 05/08/1982 Uninfected 
 3 R2 05/01/1983 Infected – chronic HCV 
X2 1 R3 03/03/1984 Infected – chronic HCV 
 2 EU2 07/01/1985 Uninfected 
 3 R4 29/04/1986 Infected – chronic HCV 
 4 R5 15/02/1987 Infected – spontaneous clearance 
X3 1 R6 16/09/1983 Infected – spontaneous clearance 
 2 R7 22/09/1986 Infected – chronic HCV 
 3 EU3 07/04/1987 Uninfected 
 4 R8 16/10/1987 Infected – spontaneous clearance 
X4 1 R9* 17/01/1989 Infected – chronic HCV 
 1 EU4* 01/02/1989 Uninfected 
X5 1 R10 03/12/1987 Infected – spontaneous clearance 
 2 R11 08/09/1988 Infected – chronic HCV 
 3 EU5 20/02/1989 Uninfected 
 4 R12 26/01/1990 Infected – chronic HCV 
X6 1 EU6* 21/06/1990 Uninfected 
 1 R13* 24/06/1990 Infected – chronic HCV 
X7 1 R14 12/12/1985 Infected – chronic HCV 
 2 R15 03/08/1988 Infected – chronic HCV 
 3 R16 17/01/1990 Infected – chronic HCV 
 4 EU7 29/10/1990 Uninfected 
 5 R17 28/03/1991 Infected – chronic HCV 
X8 1 R18 11/04/1989 Infected – spontaneous clearance 
 2 R19* 22/11/1990 Infected – spontaneous clearance 
 2 EU8* 25/11/1990 Uninfected 
*Received blood product from the same donation 
EU, exposed uninfected; HCV, hepatitis C 
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